Amphastar Pharmaceuticals, Inc. (AMPH)
23.73
+0.77
(+3.35%)
USD |
NASDAQ |
Sep 02, 16:00
23.73
0.00 (0.00%)
After-Hours: 20:00
Amphastar Pharmaceuticals Research and Development Expense (Annual) : 71.24M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 71.24M |
| December 31, 2024 | 61.43M |
| December 31, 2023 | 63.89M |
| December 31, 2022 | 64.71M |
| December 31, 2021 | 49.70M |
| December 31, 2020 | 57.08M |
| December 31, 2019 | 60.26M |
| December 31, 2018 | 52.43M |
| Date | Value |
|---|---|
| December 31, 2017 | 38.46M |
| December 31, 2016 | 36.46M |
| December 31, 2015 | 33.27M |
| December 31, 2014 | 24.70M |
| December 31, 2013 | 29.78M |
| December 31, 2012 | 29.06M |
| December 31, 2011 | 29.33M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Viatris, Inc. | 952.50M |
| Supernus Pharmaceuticals, Inc. | 104.13M |
| Liquidia Corp. | 38.45M |
| ANI Pharmaceuticals, Inc. | 51.66M |
| Corcept Therapeutics, Inc. | 254.91M |